louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04212871: The Effect of Mukbang on the Desire to Eat
Official title: The Effect of Mukbang on the Desire to Eat
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mukbang
Keywords: mukbang
desire to eat
Lead sponsor: Cornell University
Sponsor class: OTHER
First posted: 2019-12-30
Enrollment: 520
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Mukbang is an online eating broadcast where a host (Asian mukbangs generally feature a young and slim female host) consumes a large amount of food while chatting with audiences. Since some dieters watch mukbang to get satiation and control their appetites, the current study is aimed at testing the effect of mukbang on the desire to eat.

Two randomized and controlled trails are conducted. The first randomized and controlled trail is conducted online using the Amazon Mturk. Participants (n=286) were randomly assigned to watch one of the following 3 videos: ramen mukbang (n=98), donut mukbang (n=97) and a non-food content video (n=91). The other study is a in person study. Participants (n=234) were randomly assigned to watch one of the following 3 videos: hotpot mukbang (n=79), hotpot cooking show (n=76) and a non-food content video (n=79).

The investigators used the self-report survey to test whether the mukbang affects the desire to eat, and participants' satiation and disgust.


Eligibility criteria: Inclusion Criteria:

* Female, age at least 18

Exclusion Criteria:

-

Primary outcomes:
measure: satiation
timeFrame: immediately after the intervention (after watching the video)
measure: disgust
timeFrame: immediately after the intervention (after watching the video)
measure: pre-video desire to eat food
timeFrame: before watching the video. Evaluating the desire to eat was the first step in the study. After reporting this pre-video desire to eat, participants then watched the video.
measure: post-video desire to eat food
timeFrame: immediately after watching the video. After watching the video, participants immediately re-evaluated their desire to eat, which is this post-video desire to eat.
Secondary outcomes:
Other outcomes:
Locations:
city: Ithaca
country: United States
facility: Cornell University
state: New York
Study officials:
References:
Clinical trial NCT03241771: Impact of Direct Outreach to Expand Access to Naloxone in the Context of Standing Orders
Official title: Impact of Direct Outreach to Expand Access to Naloxone in the Context of Standing Orders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Opioid Abuse
Overdose
Risk Behavior
Lead sponsor: Kaiser Permanente
Sponsor class: OTHER
Collaborators: name: Denver Health and Hospital Authority
name: National Institute on Drug Abuse (NIDA)
First posted: 2017-08-07
Enrollment: 325
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: In the setting of naloxone standing orders, this study will assess if direct outreach with a web-based "Naloxone Navigator 1.0" to patients prescribed chronic opioid therapy (COT) changes opioid risk behaviors, increases naloxone uptake, and increases knowledge about overdose and naloxone

Detailed description: This is a randomized study of a web-based naloxone educational resource (Naloxone Navigator 1.0) for adults prescribed chronic opioid therapy. This study will be conducted under new naloxone standing order legislation passed in Colorado. The Naloxone Navigator 1.0 will provide online training on how to recognize an opioid overdose and respond using naloxone. There will be two arms: one will receive a link to the Naloxone Navigator 1.0 and the other will receive usual care (no link). Outcomes will include opioid risk behavior, overdose and naloxone knowledge, naloxone dispensings, and overdose rates.

Eligibility criteria: Inclusion Criteria:

* 18 years of age or greater prescribed chronic opioid therapy

Exclusion Criteria:

* Non-English speaking, hospice enrollment, do-not-resuscitate order, receipt of naloxone in the last 12 months, no internet access, not planning to continue to receive care in the same setting for the next 4 months.

Primary outcomes:
measure: Risk Behavior
timeFrame: 4 months
Secondary outcomes:
measure: Patient Knowledge
timeFrame: Within 1 month of study enrollment
measure: Naloxone Dispensings
timeFrame: 4 months
measure: Opioid dose
timeFrame: 4 months
measure: Drug Use Risk Behavior
timeFrame: 4 months
measure: Alcohol Use Risk Behavior
timeFrame: 4 months
Other outcomes:
measure: Pain Intensity
timeFrame: 4 months
measure: Overdose
timeFrame: 4 months
Locations:
city: Denver
country: United States
facility: Denver Health
state: Colorado
Study officials:
affiliation: Kaiser Permanente
name: Ingrid Binswanger, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Kaiser Permanente
name: Jason Glanz, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03379571: Competing Risk of Death and ESRD in Incident CKD Patients
Official title: Competing Risk of Death and End-stage Renal Disease in Incident Chronic Kidney Disease (Stages 3 to 5): the EPIRAN Community-based Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Kidney Diseases
Keywords: Chronic kidney disease
Competing-risk analysis
Epidemiological study
Incidence
Outcomes
Risk factors
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2017-12-20
Enrollment: 631
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population was incident CKD patients (stages 3 to 5) : all adult patients (≥18 years) residing in the given geographical area and having a first serum creatinine value ≥1.7 mg/dL reached after January 1st, 2004 and present for at least 3 months.

Brief summary: Although chronic kidney disease (CKD) affects a growing number of people, epidemiologic data on incident CKD in the general population are scarce. Screening strategies to increase early CKD detection have been developed.

Methods: From a community-based sample of 4,409 individuals residing in a well-defined geographical area, investigators determined the number of patients having a first serum creatinine value ≥1.7 mg/dL and present for at least 3 months that allowed us to calculate an annual incidence rate of CKD (stages 3 to 5). CKD (stages 3 to 5) was defined by estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m2. Investigators also described the primary care, outcomes and risk factors associated with outcomes using competing risks analyses for these CKD patients.


Eligibility criteria: Inclusion Criteria:

* \>= 18 years
* first serum creatinine value ≥1.7 mg/dL reached after January 1st, 2004
* and present for at least 3 months
* residing in the given geographical area (the Urban Community of Greater Nancy (UCGN))

Exclusion Criteria:

* \<18 years
* prevalent CKD patient : CKD diagnosis before January 1st, 2004
* patients on dialysis or renal transplanted
* refusal of participation

Primary outcomes:
measure: annual incidence rate of CKD
timeFrame: inclusion
Secondary outcomes:
measure: dialysis initiation
timeFrame: through study completion, 6 year after study start
measure: death
timeFrame: through study completion, 6 year after study start
measure: management of CKD patients
timeFrame: through study completion, 6 year after study start
Other outcomes:
Locations:
Study officials:
affiliation: CHRU de Nancy
name: Michèle KESSLER, PU-PH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00039871: PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)
Official title: PEG-Intron Plus REBETOL for the Treatment of Subjects With Chronic Hepatitis C Who Failed to Respond to Previous Combination Therapy (Any Alpha Interferon Treatment in Combination With Ribavirin)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hepatitis
Hepatitis C, Chronic
Fibrosis
Liver Cirrhosis
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2002-06-14
Enrollment: 2333
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this study is to determine the effectiveness of PEG-Intron 1.5 ug/kg/wk plus REBETOL (ribavirin) 800-1400 mg/day in adults with chronic hepatitis C with moderate to severe liver fibrosis or cirrhosis who failed to respond to previous treatment with an alpha interferon in combination with ribavirin. Patients who do not respond to PEG-Intron plus REBETOL (ribavirin) will be enrolled in a long-term maintenance study to evaluate the effectiveness of PEG-Intron monotherapy versus no treatment for the prevention of disease progression (Protocols P02569 and P02570).


Eligibility criteria: Inclusion Criteria:

* Age at entry 18-65
* Positive for Hepatitis C
* Nonresponder to previous treatment (minimum of 3 months) with an alpha Interferon plus ribavirin
* Liver biopsy demonstrating moderate to severe fibrosis or cirrhosis

Exclusion Criteria:

* Any cause for the liver disease other than chronic hepatitis C
* History or presence of complications of cirrhosis
* Alcohol or illicit drug use or methadone treatment within the past 2 years
* Treatment for chronic hepatitis C within the previous 6 months
* Diseases or conditions that could interfere with the subject's participation in and completion of the study

Primary outcomes:
measure: Sustained Virologic Response (SVR) Rate
timeFrame: Assessed at end of 24 weeks posttreatment follow-up
Secondary outcomes:
measure: Sustained Virologic Response (SVR) for Participants With Undetectable HCV-RNA at Treatment Week 12
timeFrame: 24 weeks posttreatment
measure: Sustained Virologic Response (SVR) for Participants With Detectable But ≥2 Log Drop in HCV-RNA at Treatment Week 12
timeFrame: 24 weeks posttreatment
Other outcomes:
Locations:
Study officials:
References:
citation: Poynard T, Munteanu M, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Goncales F, Diago M, Craxi A, Silva M, Boparai N, Griffel L, Burroughs M, Brass C, Albrecht J. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC(3) program. J Hepatol. 2011 Feb;54(2):227-35. doi: 10.1016/j.jhep.2010.06.038. Epub 2010 Sep 15.
Clinical trial NCT05880771: Immediate Implant Placement: a Clinical and Radiographic Study on Hard and Soft Tissues Retraction at One Year.
Official title: Immediate Implant Placement: a Clinical and Radiographic Study on Hard and Soft Tissues Retraction at One Year.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Immediate Implant Placement
Guided Surgery
Immediate Tamporization
Lead sponsor: Saint-Joseph University
Sponsor class: OTHER
First posted: 2023-05-30
Enrollment: 30
Sex: ALL
Minimum age (years): 35
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This project consists of placing dental implants at extraction sites. Bone drilling and implant placement are performed using the flapless method with the use of a surgical guide allowing guided surgery. After implant placement, temporary teeth are immediately made and placed on the implants to guide the gingival contour.

Bone and soft tissue retraction at the implanted sites are measured radiographically and digitally using surface scan superimposition over a 12-month period.


Eligibility criteria: Inclusion Criteria:

* Absence of systemic or osseous disease that may impair peri-implant healing
* Age ≥ 21 years
* Acceptable oral hygiene
* Presence of both adjacent teeth
* Absence of acute infection in the treated area
* Absence of periodontal pockets \> 3mm at the concerned site
* Absence of pre-operative defect at the buccal bone wall (dehiscence or fenestration)
* Per-operative integrity of the osseous and gingival structures (during tooth extraction)
* Light or non-smoker (\<10 cigarettes per day)

Exclusion Criteria:

* Myocardial infarction within the past 6 months.
* Poorly controlled diabetes (HBA1c \> 7.5%).
* Coagulation disorders.
* Radiotherapy to the head/neck area within the past two years.
* Present or past treatment with intravenous bisphosphonates.
* Immunocompromised patients.
* Psychological or psychiatric problems.
* Alcohol or drug abuse.
* Poor oral hygiene and motivation (full mouth plaque score \> 30% and/or full mouth bleeding score \> 20%).
* Uncontrolled periodontal disease.

Primary outcomes:
measure: Hard tissue change by superimposing CBCT scans between 0 and 12 months using 3d slicer software
timeFrame: 12 months
measure: Soft tissue change by superimposing surface intraoral scans between 0 and 12 months using 3d slicer software
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Beirut
country: Lebanon
facility: Saint Joseph University
Study officials:
References:
Clinical trial NCT02008071: Effects of a Minimal-Contact Lifestyle Intervention on Physical Activity, Diet, and Body Weight
Official title: Effects of a Minimal-Contact Lifestyle Intervention on Physical Activity, Diet, and Body Weight
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Weight Loss
Lead sponsor: University of Tennessee
Sponsor class: OTHER
First posted: 2013-12-11
Enrollment: 57
Sex: ALL
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to conduct a pilot randomized controlled trial, to determine whether providing financial incentives for meeting daily step goals (a) increases the daily step counts of participants, (b) increases compliance with the overall program (including diet recommendations), and (c) increases weight loss.


Eligibility criteria: Inclusion Criteria:

* required to be able to read.
* required to have access to a computer.
* required to have a body mass index between 27 and 45 kg.m-2.
* required to take fewer than 7,000 steps per day at baseline (as determined by a pedometer, averaged across 4-7 days).

Exclusion Criteria:

* Individuals who report having an injury or physical limitation that renders them unable to walk ¼ mile without difficulty.
* Uncontrolled cardiovascular or metabolic condition determined by health history questionnaire.

Primary outcomes:
measure: Daily Step Count
timeFrame: Change from week 1 to week 12
Secondary outcomes:
measure: Program Compliance
timeFrame: Change from week 1 to week 12
Other outcomes:
measure: Weight Loss
timeFrame: Change from week 1 to week 12. There will also be measures taken 3 months following week 12
Locations:
city: Knoxville
country: United States
facility: University of Tennessee
state: Tennessee
Study officials:
References:
Clinical trial NCT04141371: Molar Sodium Lactate Filling in Severe Meningeal Hemorrhage
Official title: Effect of Molar Sodium Lactate Filling on Cerebral Hemodynamics in Patients With Severe Meningeal Hemorrhage Multicenter Randomized Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Subarachnoid Hemorrhage, Aneurysmal
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2019-10-28
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Subarachnoid hemorrhage by aneurysmal rupture is a serious condition associated with a high mortality rate. Among the complications presented by these patients, vasospasm is one of the main causes of secondary aggravation, in particular the appearance of delayed neurological deficits following the induced cerebral ischemia. Classically occurring between the 4th and 12th day, with a peak on D7, its prevention is currently often ineffective.

In recent years, many studies have shown that sodium lactate could be an interesting product for neuroprotection. In addition to an anti-osmotic effect that has been demonstrated by our team in the context of post-traumatic intracranial hypertension, a metabolic action has also been observed in periods of metabolic attacks induced by brain attacks. Recently, a vasodilatory action of sodium lactate has been observed from an experimental and clinical point of view.

The purpose of this work is to observe the effect of sodium lactate, compared to placebo, on cerebral hemodynamics measured by perfusion CT (Mean Transit Time MTT) in a population of patients with hemorrhage under the arachnoid.

This work is the preliminary work of a study that will investigate the potential preventive protective effect of sodium lactate on the incidence of vasospasm.


Eligibility criteria: Inclusion Criteria:

* Any patient over 18 years of age with severe meningeal hemorrhage defined by a WFNS≥3 score will be included in the study.
* Treated by endovascular embolization or surgically within 48 hours
* After obtaining the informed consent of the patient, or his relatives if he is not searchable (coma).
* Affiliation to a social security system
* After an adapted preliminary medical examination

Exclusion Criteria:

* Post-traumatic meningeal hemorrhage
* Management time \>48h with respect to bleeding
* Known neurodegenerative pathology (Alzheimer's, Parkinson's, etc.), Creutzfeldt-Jacob disease
* Pregnant woman
* Decision not to treat
* Refusal to participate in the study
* Adult patient protected by law
* Person deprived of administrative or judicial freedom

Primary outcomes:
measure: median transit time (MTT)
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Grenoble
country: France
facility: Grenoble Hospital
city: Marseille
country: France
facility: Marseille Hospital
city: Nice
country: France
facility: Carole ICHAI
Study officials:
References:
Clinical trial NCT04276571: EMPATIA@Lecco- Balance Rehabilitation of Autistic Children With Virtual rEality
Official title: EMPATIA@Lecco- Balance Rehabilitation of Autistic Children With Virtual rEality
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Autism Spectrum Disorder
Keywords: motor abilities
Lead sponsor: IRCCS Eugenio Medea
Sponsor class: OTHER
First posted: 2020-02-19
Enrollment: 22
Sex: ALL
Minimum age (years): 7
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The general objective of this project is to investigate the possible efficacy of a training based on proprioceptive and visual feedback carried out with the GRAIL (Motekforce Link) virtual reality environment on postural control and balance skills of school-aged children with clinical diagnosis of ASD.


Eligibility criteria: Inclusion Criteria:

* a clinical diagnosis of ASD
* All participants were required to have estimated FSIQ of 80 or above

Exclusion Criteria:

* using any stimulant or non-stimulant medication that affects the central nervous system
* having an identified genetic disorder
* having vision or hearing problems
* suffering from chronic or acute medical illness
* presence of epilepsy

Primary outcomes:
measure: experimental balance assessment
timeFrame: approximately 6 weeks after starting the intervention
measure: Movement Assessment Battery for Children 2 (MABC2) (Henderson et al., 2007).
timeFrame: approximately 6 weeks after starting the intervention
Secondary outcomes:
measure: Developmental Coordination Disorder Questionnaire (DCDQ) (Wilson et al., 2007).
timeFrame: approximately 6 weeks after starting the intervention
measure: assessment of balance in response to perturbation applied by accelerating the dual-belt treadmill the dominant side at toe-off
timeFrame: approximately 6 weeks after starting the intervention
measure: assessment of overground balance using GSENSOR (BTS Bioengineering), a medical device for motion analysis
timeFrame: approximately 6 weeks after starting the intervention
measure: evaluation of gait features using the GRAIL (Motekforce Link)
timeFrame: approximately 6 weeks after starting the intervention
Other outcomes:
Locations:
city: Bosisio Parini
country: Italy
facility: Scientific Institute IRCCS E. Medea
state: Lecco
Study officials:
References:
citation: Biffi E, Costantini C, Ceccarelli SB, Cesareo A, Marzocchi GM, Nobile M, Molteni M, Crippa A. Gait Pattern and Motor Performance During Discrete Gait Perturbation in Children With Autism Spectrum Disorders. Front Psychol. 2018 Dec 11;9:2530. doi: 10.3389/fpsyg.2018.02530. eCollection 2018.
Clinical trial NCT00884871: Study of Surgically-Induced Weight Loss on Pelvic Floor Disorders
Official title: A Prospective Cohort Study of the Impact of Surgically-Induced Weight Loss on Pelvic Floor Disorders
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pelvic Floor Disorders
Keywords: pelvic floor disorders
weight loss
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
First posted: 2009-04-21
Enrollment: 100
Sex: FEMALE
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 100 obese women who have met surgical eligibility for laparoscopic adjustable gastric banding at the Center for the Treatment of Obesity at UCSD

Brief summary: The specific aim of this study is to evaluate the effect of surgically-induced weight reduction, as achieved by laparoscopic gastric banding or sleeve gastrectomy, on pelvic floor disorders such as stress urinary incontinence, overactive bladder, anal incontinence, and pelvic organ prolapse in severely, morbidly and super-obese women using a prospective, observational study design.


Eligibility criteria: Inclusion Criteria:

* surgical eligibility met by Center for the Treatment Obesity criteria
* morbid obesity (BMI \> 40 kg/m2) or severe obesity (BMI \> 33 kg/m2) in presence of NIH co-morbidities
* willing to participate in study, including completion of self-reported questionnaires

Exclusion Criteria:

* pregnancy or planned pregnancy
* recent pregnancy or pelvic surgery
* age \< 21 years
* known neurologic disease or pelvic pathology

Primary outcomes:
measure: Prevalence of pelvic floor disorders ascertained by Epidemiology of Prolapse and Incontinence Questionnaire
timeFrame: 12 months
Secondary outcomes:
measure: Weekly incontinence episodes and pad use ascertained by incontinence diary
timeFrame: 12 months
measure: Quality of life impact ascertained by validated measures (PFIQ, PFDI, FISI, and PGI-I)
timeFrame: 12 months
measure: Sexual function ascertained by validated measure (PISQ)
timeFrame: 12 months
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: University of California San Diego Medical Center
state: California
Study officials:
affiliation: University of California, San Diego
name: Emily L Whitcomb, M.D.
role: PRINCIPAL_INVESTIGATOR
References: